Importance of breath tests for the evaluation liver function in patients with chronic kidney disease

Czech version

Authors: Nikola Mejzlíková ¹; Karolína Krátká ¹; Miluše Vejvodová ¹; Pavla Libicherová ¹; Nikola Uzlová ¹; Jana Vránová ²; Ivan Rychlík ¹
Authors‘ workplace: I. interní klinika 3. LF UK a FN Královské Vinohrady, Praha ¹; Ústav lékařské biofyziky a lékařské informatiky 3. LF UK Praha ²
Published in: Vnitř Lék 2020; 66(3): 50-52
Category:

Overview

Breath tests for the evaluation liver metabolic function are a non-invasive diagnostic method with high sensitivity and specificity. Up today, the issue of liver damage in patients with chronic kidney disease has not been investigated sufficiently, although it might have significant clinical consequences. The following article describes the principles of breath tests, experiences with breath tests in patients with chronic kidney disease (CKD) and the results of our pilot study with methacetin breath tests in patients with CKD and in regular peritoneal dialysis treatment.

Keywords:

13C‑methacetin breath test – chronic kidney disease – kidney‑liver organ cross talk – metabolic liver function

Sources

1. Armuzzi A, Candelli M, Zocco MA, et al. Review article: breath testing for human liver function assessment. Aliment Pharmacol Ther 2002; 16 : 1977–1996.

2. Matsumoto K, Suehiro M, Iio M, et al. 13C)methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987; 32 : 344–348.

3. Leblond F, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28 : 1317–1320.

4. Leblond F, Guévin C, Demers C, et al. Downregulation of hepatic cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2001; 12 : 236–232.

5. Guévin C, Michaud J, Naud J, et al. Down‑regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002; 137 : 1039–1046.

6. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A aktivity in patients with end‑stage renal disease. Clin Pharmacol Ther 2003; 73 : 427–434.

7. Nolin TD, Appiah K, Kendrick SA, et al. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006; 17 : 2363–2367.

8. Michaud J, Nolin TD, Naud J et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108 : 157–163.

9. Michaud J, Dubé P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005; 144 : 1067–1077.

10. Joy MS, Frye RF, Nolin TD, et al. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy 2014; 34 : 114–122.

11. Michaud J, Naud J, Chouinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006; 17 : 3041–3048.